The company works with pharma and biotech to help with drug developmentRead more...
Firms include Chiesi Ventures, Frazier Healthcare Partners, OrbiMed, and Atlas Venture
In the United States alone 25 million people suffer from rare disease, a number that jumps to 400 million people globally. While 1 in 10 people will suffer from a rare disease at some point in your life, half of all rare diseases don’t have a foundation or research support group.
The problem is that, as the name suggests, these diseases don't affect enough people to make a financial difference, so they're overlooked, but the effect is cumulative, and financially devastating for those who have them, as well as on the system: the cost per patient per year for those with a rare disease ranged from $8,812 to $140,044 for rare diseases patients compared to $5,862 for those without a rare disease.
Thanks to advances in technology, though, it is becoming more viable for companies to focus on these rare diseases. That is most especially true for biotech companies which can use genomics and AI to help develop treatments for these patient.
Venture investors are also looking at this space, investing $8.8 billion in 106 rare disease focused drug developers in 2021, and $5.2 billion across 71 investments in 2022.
Here are some of the VCs who have invested in rare diseases and their investments:
Description: "Chiesi Ventures is a venture capital firm focused on the area of rare and orphan disorders. Our goal is to complement the strategic interest of the Chiesi Group by investing in early stage development opportunities. Chiesi Ventures also aim to accelerate the expansion of the Chiesi network in EU and the US among universities, venture capital investors, rare disease patient organizations and entrepreneurial companies developing treatments for rare diseases"
Fund size: Unknown
Investments: Curasen, Aura Biosciences, Glycomine, Reneo
Description: "Working with entrepreneurs to turn breakthrough science into breakthrough medicine"
Fund size: $2 billion under management
Investments: Zogenix, Dicerna Pharmaceuticals
Description: "The Frazier Life Sciences team invests in and builds companies developing and commercializing novel therapeutics"
Fund size: $4.8 billion under management
Investments: Amicus Therapeutics, Passage BioOrbiMed
Description: "From biopharmaceuticals to medical devices, digital health, diagnostics, and healthcare services, OrbiMed is scouting the globe for innovations that will help ensure humanity lives healthier, longer, and more productive lives"
Fund size: $17 billion under management
Investments: Passage Bio, Disc Medicine, Invitae
Description: "Access Biotechnology invests in transformative therapies for conditions with high unmet needs and that have the potential to meaningfully impact human health"
Fund size: Unknown
Investments: Passage Bio, Disc MedicineBain Capital Life Sciences
Description: "Bain Capital Life Sciences invests in pharmaceutical, biotechnology, medical device, diagnostic, and life science tool companies across the globe, with a focus on companies that both drive medical innovation across the value chain and enable that innovation to improve the lives of patients with unmet medical needs"
Fund size: $180 billion under management
Investments: Disc Medicine, Dicerna Pharmaceuticals
Description: "Logos, the Greek word for logic and discourse, emphasizes our philosophy of seeking empirical truth and rigorous scientific diligence across our investment endeavors"
Fund size: $200 million
Investments: Passage Bio, Dyne Therapeutics
Description: "We build breakthrough biotech companies with remarkable life science entrepreneurs"
Fund size: $2.2 billion under management
Investments: Disc Medicine, Dyne Therapeutics
Description: "Surveyor Capital is a longstanding fundamental equities business at Citadel, established in 2008. Our sector-aligned investment teams conduct deep fundamental research, developing an independent view on the companies they cover. They are specialists in their industries and experts in their coverage, building trusted relationships with many corporate management teams"
Fund size: Unknown
Investments: Dyne Therapeutics, RezoluteNew Leaf Venture Partners
Description: "New Leaf Venture Partners believes in leveraging innovation to advance healthcare technology. We invest in great people who are building tomorrow’s leading-edge businesses"
Fund size: $605.5 million undermanagement
Investments: Passage Bio, Rallybio, BrightInsight
Description: "5AM Ventures is a leading venture capital firm focused on building next-generation life science companies capable of delivering outstanding returns to our investors"
Fund size: $450 million and $300 million
Investments: Disc Medicine, RallybioCanaan Partners
Description: "Canaan is an early-stage venture capital firm that invests in visionaries with transformative ideas"
Fund size: $6.8 billion
Investments: Amicus Therapeutics, RallybioNovo Holdings
Description: "Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation, one of the world’s largest philanthropic enterprise foundations"
Fund size: EUR 108 billion under management
Investments: Disc Medicine, MedGenome
(Image source: news-medical.net)
Support VatorNews by Donating
Read more from our "Trends and news" series
The company plans to open clinics in New Jersey, Connecticut, and Maryland next yearRead more...
Practices can increase their business through memberships, patient financing, and mobile rewardsRead more...